Zengqing Guo

机构：Fujian Medical University, Jiangsu Cancer Hospital, Fujian Provincial Cancer Hospital · ORCID：0000-0002-9645-5186

发表论文 148 篇 · 总被引 3397 次 · h-index 29

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. (2024 · Journal of Clinical Oncology · 被引 21)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• Burden of colon and rectum cancer attributable to processed meat consumption in China, 1990–2021 (2025 · Frontiers in Nutrition · 被引 14)
• Long-term trends and projections of stomach cancer burden in China: Insights from the GBD 2021 study (2025 · PLoS ONE · 被引 13)
• Trends and projections of gallbladder and biliary tract cancer in China: a comprehensive analysis from 1990 to 2030 based on the Global Burden of Disease Study 2021 (2025 · BMC Public Health · 被引 7)